Mutations in the tumor suppressor gene LKB1 are important in hereditary Peutz -Jeghers syndrome, as well as in sporadic cancers including lung and cervical cancer. LKB1 is a kinase-activating kinase, and a number of LKB1-dependent phosphorylation cascades regulate fundamental cellular and organismal processes in at least metabolism, polarity, cytoskeleton organization, and proliferation. Conditional targeting approaches are beginning to demonstrate the relevance and specificity of these signaling pathways in development and homeostasis of multiple organs. More than one of the pathways also appear to contribute to tumor growth following Lkb1 deficiencies based on a number of mouse tumor models. Lkb1-dependent activation of AMPK and subsequent inactivation of mammalian target of rapamycin signaling are implicated in several of the models, and other less well characterized pathways are also involved. Conditional targeting studies of Lkb1 also point an important role of LKB1 in epithelial -mesenchymal interactions, significantly expanding knowledge on the relevance of LKB1 in human disease.
Introduction
Cancer arises as a result of accumulating genetic and epigenetic changes, which compromise the cell's ability to control its identity and proliferation. Many identified tumor suppressors play a well-established role in regulation of cell growth and division (e.g. Rb, APC, p21, PTEN) and genome maintenance (e.g. p53, BRCA1-2, ATM, ATR, MLH1, MSH2), providing a logical link between the loss of gene product and promotion of carcinogenesis. An interesting exception is the serine/threonine kinase gene LKB1 (also known as STK11), which has in recent years taken a prominent position among tumor suppressors. Heterozygous germline mutations in LKB1 predispose to Peutz -Jeghers syndrome (PJS) where patients develop benign polyps in the gastrointestinal (GI) tract and are in high risk of developing malignant tumors in GI tract, breast, and gynecological organs (Giardiello et al., 2000) . Importantly, somatic LKB1 mutations are found at least in lung and cervical cancer (Wingo et al., 2009) . Through phosphorylation of several cellular kinases LKB1 has been implicated in control of cellular and organismal metabolism, cell polarity, and a variety of other functions ranging from proliferation and migration to senescence, apoptosis, DNA damage response and differentiation (Vaahtomeri and Mäkelä, 2011) . Despite these many functions attributed to LKB1, the specific contributions to the maintenance of tissue homeostasis in vivo and tumor growth are only sketchily appearing with the development of LKB1 mouse models. This work is important to enable rational treatment strategies to LKB1-deficient tumors.
The LKB1 kinase acts in a trimer with a pseudokinase STRAD and the scaffold protein MO25 to phosphorylate at least 14 kinases with conserved activation sites (Katajisto et al., 2007) . A well-known substrate of LKB1 is AMPK, which is the master regulator of cellular and organismal metabolism, providing a putative downstream pathway to LKB1-mediated tumor suppression (Shackelford and Shaw, 2009) . In mouse studies, AMPK requires LKB1 for activation in vivo in most tissues (Sakamoto et al., 2005; Shaw et al., 2005; Contreras et al., 2008; . AMPK senses the energy state of cells through monitoring AMP levels as a sensitive readout for ATP. AMPK is activated following exercise, hypoxia, or glucose deprivation, after which it phosphorylates multiple targets to increase energy uptake and catabolic processes such as glucose uptake and fatty acid oxidation, and suppress anabolic processes such as lipogenesis and cholesterol synthesis (Hardie et al., 2003) .
AMPK is the potential candidate to mediate LKB1's effects in cell growth via the mammalian target of rapamycin (mTOR) signaling (Corradetti et al., 2004; Shaw et al., 2004) , which is the pathway monitoring the availability of nutrients in regulation of cell size and protein synthesis as well as proliferation (Zoncu et al., 2011) . Increased mTOR signaling is common in cancer (Guertin and Sabatini, 2007) and also present in at least some Lkb1-deficient tumors (Shaw et al., 2004; Ji et al., 2007; Contreras et al., 2008; ). An additional link between LKB1 and mTOR pathway may lie in regulation of PI3K-Akt pathway inhibitor PTEN by LKB1 (Mehenni et al., 2005) .
Loss of cell polarity is commonly noted in cancer, and LKB1 is an important factor for cell polarity in different organisms. In C. elegans, the orthologs for LKB1 (par-4) and MARKs (par-1) were identified in a panel of six partitioning (par) mutants which disrupted the polarity of the early embryos (Kemphues et al., 1988) . In Drosophila, Lkb1 is required for proper oocyte polarity (Martin and St Johnston, 2003) . In mammalian cells, in both 2D and 3D cell culture models and in vivo, LKB1 is known to regulate polarity (Baas et al., 2004; Partanen et al., 2007; . Polarity defects are, however, not seen in all Lkb1-deficient tumors (Contreras et al., 2008 (Contreras et al., , 2010 . Several of the LKB1 substrates have been reported to mediate the regulation of cell polarity through regulating the cytoskeleton and formation of cell -cell junctions. MARK kinases are implicated in the stability of microtubules by phosphorylating and thereby dissociating microtubule-associated proteins (MAPs), for example the tau protein, from microtubules (Drewes et al., 1997; Stoothoff and Johnson, 2005) . Neuronal polarity and axon formation are regulated by LKB1 at least partially via BRSK kinases (Kishi et al., 2005; Barnes et al., 2007) . To what extent LKB1 acts as a polarity protein in mammalian non-neuronal cells still remains to be determined, although at least in both exo-and endocrine pancreas Lkb1 loss leads to polarity defects in vivo Granot et al., 2009) . As formation of stress fibers is essential in cell contractility, recent studies associate LKB1 with cell motility via NUAK1 and NUAK2, which have been implicated in regulation of myosin light chain phosphorylation (Vallenius et al., 2010; Zagorska et al., 2010) .
For detailed information of the molecular signaling pathways of Lkb1, the reader is recommended recent reviews more focused on that topic (Katajisto et al., 2007; Hezel and Bardeesy, 2008; Vaahtomeri and Mäkelä, 2011) .
Role of Lkb1 in development and tissue homeostasis in mice
Although LKB1 is a tumor suppressor, inactivation of Lkb1 through homologous recombination or 'knock-out' (KO) does not always lead to tumors. This is due partly to essential functions of Lkb1 in development and partly demonstrates the tissue-specificity of Lkb1 functions, where in some cell types biallelic deletion is detrimental to cells or affects specific functions in metabolism as summarized in Figure 1 and discussed below.
Role of Lkb1 in embryogenesis
Generation of full KO revealed that Lkb1 is essential for embryogenesis; no viable Lkb1 2/2 embryos were seen after E11.
Analysis of the E8.5-E9.5 embryos revealed severe developmental defects including impaired neural tube closure and somitogenesis, mesenchymal tissue cell death, and defective vasculature. The extra-embryonic tissues (yolk sac and placenta) were also deformed. VEGF signaling was highly upregulated in the KO Figure 1 Non-tumorigenic phenotypes following Lkb1 targeting in mice. Phenotypes (green) are grouped according to tissue type, cell type affected/analyzed (blue), and alleles used for targeting. When appropriate, activator of deletor is indicated in purple. Noted signaling change(s) indicated in red. Alleles as displayed in original publications except for Lkb1 flox2h/flox2h hypomorphic Lkb1 (Sakamoto et al, embryos, possibly relating to the vascular phenotype (Ylikorkala et al., 2001) . Embryonic lethality, no embryonic turning, and small somites were also shown in another report of Lkb1 full KO (Jishage et al., 2002) . The severe developmental defect was not a result of the abnormal extra-embryonic tissues, since epiblast-specific conditional inactivation of Lkb1 using Mox1-Cre resulted in very similar embryonic lethal phenotype to full KO (Londesborough et al., 2008) . The important role of Lkb1 in development and maintenance of neurons, mesenchymal cells, and vascularization has been recapitulated in tissuespecific Lkb1 KOs. Role of Lkb1 in angiogenesis Londesborough et al. (2008) further dissected the role of Lkb1 in endothelia by deleting Lkb1 in vascular endothelial cells using Tie1-Cre (Figure 1) . The mice died at E12.5 and displayed dilated embryonic vessels and pericardial swelling. The vessels were irregular and distorted and suffered from inadequate supportive vascular smooth muscle cell layer. Since Tgfb signaling was reduced both in Lkb1-deficient mouse yolk sacs and human umbilical vein endothelial cells (HUVECs) where LKB1 expression was silenced by siRNA, the vascular phenotype was suggested to result from a loss of supporting vascular smooth muscle cells as a consequence of attenuated Tgfb signaling from endothelial cells (Londesborough et al., 2008) . Another report also described mice lacking Lkb1 in endothelial cells, deleted using Tie2-Cre driver (Ohashi et al., 2010) (Figure 1 ). This study repeated the finding that endothelial Lkb1 is essential for proper embryonic development and no homozygous mutants were born. Analysis of heterozygous Tie2-Cre;Lkb1 flox/+ mice revealed that the mice, including vasculature, seemed phenotypically normal, but displayed reduced revascularization after hind-limb ischemia. Studies in mouse tissues, primary mouse endothelial cells, and HUVECs implemented that the phenotype was mediated via AMPK (Ohashi et al., 2010) . In this study, the authors did not address the contribution of Tgfb signaling to the observed phenotype. In the Tie2-Cre model, Lkb1-AMPK axis seemed to mediate proangiogenetic signaling as Lkb1 heterozygosity resulted in reduction of revascularization in adult mice (Ohashi et al., 2010) . In developing embryo, increased VEGF signaling upon Lkb1 loss would suggest the opposite, antiangiogenic role for Lkb1 (Ylikorkala et al., 2001) . Also in the context of PJS polyps where a loss of Lkb1 leads to increased HIF1a and vasculature, Lkb1 seems to be rather antiangiogenic . However, reduced capillary density was reported in mice where Lkb1 was conditionally deleted from the heart (Ikeda et al., 2009) . In 3D culture system where endothelial cells are embedded in Matrigel, both over-expression (Xie et al., 2009) and inhibition (Ohashi et al., 2010) of Lkb1 have been reported to inhibit network formation, suggesting proper expression of Lkb1 is essential for angiogenesis. Thus, the precise role of Lkb1 in angiogenesis seems to be dependent on the tissue type and/ or the developmental phase, varying from inhibition to promotion.
Role of Lkb1 in liver
The finding that Lkb1 functions upstream of AMPK (Shaw et al., 2004) led to interest to study its effects in liver, where many pathways of carbohydrate and lipid metabolism, including glycogenesis, glycogenolysis, gluconeogenesis, lipogenesis, and cholesterol synthesis take place. Tail-vain injection of Adeno-Cre to mice carrying conditional Lkb1 allele led to hepatocyte-specific Lkb1 deletion since Adeno-Cre has high tropism for hepatocytes (Shaw et al., 2005) (Figure 1 ). Lkb1 loss resulted in nearly complete abolishment of AMPK activation in liver, and the glucose metabolism of the mice was impaired as demonstrated by elevated blood glucose. CRTC2 phosphorylation was reduced in the livers of the mice, leading to elevated CREB-mediated transcription, including expression of PGC1a and other gluconeogenetic genes. Also lipogenetic genes were over-expressed. Metformin, the diabetes drug which reduces blood glucose levels via AMPK pathway (Zhou et al., 2001) , did not lower blood glucose in the liver-specific Lkb1 KO mice, demonstrating that AMPK activity induced by Lkb1 in liver is required for the effects of metformin in vivo. In another report of liver-specific Lkb1 KO using Alb-Cre driver, Woods et al. (2011) reported defective bile ducts in liver, leading to accumulation of bile in liver and serum (Figure 1 ). Bile salt export pump was not located in canalicular membrane of the bile canaliculi, indicating possible defects in cell polarity. The mice also suffered from cholestasis (Woods et al., 2011) . These reports of liver-targeted deletions of Lkb1 demonstrate the critical requirement of Lkb1 in glucose, lipid, bile, and cholesterol metabolism. Furthermore, they show that in liver, Lkb1 is the main activator of AMPK, and its activity is required for the AMPK-mediated suppression of lipogenesis and gluconeogenesis to take place.
Role of Lkb1 in muscle
Muscles are highly energy-consuming tissues whose glucose homeostasis needs to be regulated both in response to insulin after blood sugar increase, and to exercise-mediated deficiency of glucose storage. Sakamoto et al. (2005) provided the first genetic evidence that Lkb1 is required for AMPK activation in vivo in skeletal muscle. They generated conditional Lkb1 mice in which cDNA of Lkb1 exons 5-7 fused with neomycin resistance cassette, surrounded by loxP sites, was inserted between exons 4 and 8 in the genomic Lkb1 locus. The resulting mice were hypomorphic and expressed only 10%-20% of normal levels of Lkb1 in the absence of Cre-mediated recombination. Using MCK-Cre driver to create muscle-specific Lkb1 KO, they found that AMPKa2 (one of the two alternative catalytic subunits of AMPK) activation by either the AMP analog AICAR, muscle contraction, or phenformin, a similar blood glucose lowering drug to metformin, was lost and AMPKa1 activation greatly reduced. Upon contraction, glucose transport to muscle cells was abolished (Sakamoto et al., 2005) . In another study using the same muscle-specific MCK-Cre with another (non-hypomorphic) conditional Lkb1 line, effects of Lkb1 loss in muscle on levels of blood glucose were investigated (Koh et al., 2006) (Figure 1) . Interestingly, glucose metabolism seemed to be enhanced in these mice, demonstrated by reduced fasting blood glucose and blood insulin concentrations, improved glucose tolerance, and increased muscle glucose uptake. This phenotype, indicating that Lkb1 in muscle functions as a negative regulator of glucose metabolism, was suggested to be resulting from improved muscle glucose uptake, mediated by increased phosphorylation of Akt and reduced the gene expression of the Akt inhibitor TRB3. Lkb1 loss abolished the activity of AMPKa2, but not AMPKa1 in muscle cells. Also MARK4, but not MARK2/3 activity was significantly reduced. Based on this study, the metabolic effects mediated by Lkb1 in muscle seem to oppose those in liver, at least in terms of blood glucose levels (Koh et al., 2006) . Recently, the Lkb1 substrate NUAK2 was proposed to be a mediator of contraction-stimulated glucose transport by skeletal muscle .
Also cardiac muscle lacking Lkb1 has been investigated. Sakamoto et al. (2006) studied the effect of Lkb1 deficiency in heart using the MCK-Cre driver, which deletes Lkb1 in both skeletal and cardiac myocytes and found that Lkb1 inactivation did not lead to overt cardiac dysfunction, although the weight of the heart was reduced and the atria enlarged; however, the study revealed that cardiac Lkb1 is required for activation of AMPKa2 both in basal conditions and in response to ischemia ( Figure 1 ). Also Jessen et al. (2010) used the MCK-Cre driver but the Lkb1 allele was not hypomorphic as in the Sakamoto et al. (2006) study. They showed that ablation of Lkb1 in heart leads to impaired cardiac function in both basic conditions and postischemia and suggested that failure to downregulate mTOR signaling by AMPKa2 activation underlined the phenotypes. Ikeda et al. (2009) used a-MHC-Cre to delete Lkb1 specifically from the heart, and a more severe phenotype was observed: the mice displayed hypertrophy and impaired function of the heart, reduction of cardiac capillary density, and increased fibrosis and collagen content and died by 6 months of age. The differences between these phenotypes may reflect differences in the timing of Cre activity, specificity of the Cre recombination, and/ or the conditional Lkb1 allele used. However, it seems clear that Lkb1 is needed for the normal function of heart in both basal and ischemic conditions.
Role of Lkb1 in pancreas
Pancreatic b-cells secrete insulin and are thus important mediators of whole-body glucose metabolism. As Lkb1-AMPK axis is important in regulation of liver metabolism and muscle glucose homeostasis, it is of interest to study whether Lkb1 has an effect on the insulin release. Granot et al. (2009) used the Pdx1-CreER driver to delete pancreatic Lkb1 in 6-week-old mice by tamoxifen injection (Figure 1) . In response to glucose injection, the mutant mice secreted more insulin than control mice, which carried the conditional Lkb1 allele but were not subjected to tamoxifen injection. Deletion of Lkb1 led to increased size of b-cells together with disrupted polarity. Increased mTOR signaling seemed to mediate the cell size increase, while the polarity defect took place at least partially through MARK2. Increased insulin secretion was partially dependent on AMPK (Granot et al., 2009 ). Fu et al. (2009 used the same Pdx1-CreER system to delete Lkb1 in adult b-cells and also found that the mice showed improved glucose tolerance, b-cell mass had increased, and mTOR pathway was activated (Figure 1) . These results place Lkb1 as an important regulator of pancreatic b-cell size, polarity, and function, further highlighting its essence in regulation of organismal metabolism. Sun et al. (2010a) investigated pancreatic b-cells with the Rip2-Cre driver, which activates Cre-mediated recombination in pancreatic b-cells and some hypothalamic neurons, and found that the mice displayed diminished food intake and weight gain, enhanced insulin secretion, and improved glucose tolerance ( Figure 1) . Also here, mTOR pathway was activated. However, the study by the same group where both AMPKa subunits were deleted in b-cells using the same Rip2-Cre showed decreased insulin secretion (Sun et al., 2010b) . This suggests that Lkb1 loss regulates mTOR signaling in b-cells partially independent of AMPK, or that the hypothalamic Lkb1 and AMPK have different functions, impacting the feeding behavior and hormonal balance.
Role of Lkb1 in immune system
Three recent studies elegantly demonstrated that Lkb1 regulates the quiescence and maintenance of hematopoietic stem cells (HSCs) using conditional Lkb1 alleles with Mx1-Cre followed by injections of polyinosinic-polycytidylic acid (pIpC), or Rosa26-CreERt2 followed by tamoxifen injections (Gan et al., 2010; Gurumurthy et al., 2010; Nakada et al., 2010) (Figure 1 ). Both approaches resulted in a similar phenotype: increased proliferation followed soon by decline in HSC number, resulting in loss of all immune cell types (pancytopenia) and death. Transplantation experiments demonstrated that Lkb1-deficient HSCs were not able to reconstitute the bone marrow of irradiated wild-type (wt) mice, nor were they able to compete with wt donor cells, demonstrating that the effect was cell-autonomous; mitochondrial defects and decreased ATP levels, as well as altered long-chain fatty acid and nucleotide metabolite levels suggested metabolic defects to underlie the phenotypes noted (Gan et al., 2010; Gurumurthy et al., 2010; Nakada et al., 2010) . Interestingly, only minor similarities in mitochondrial phenotypes were found when mice defective for both AMPKa subunits were compared with Lkb1 KO mice (Nakada et al., 2010) , implicating other Lkb1 substrates in these phenotypes. Consistent with this, rapamycin or AMPK activators AICAR and A769662 did not rescue the phenotype in any of the studies. Immune cell apoptosis was increased, and Lkb1-deficient HSCs also demonstrated increased autophagy in bone marrow, and inhibiting this further decreased immune cell survival (Gan et al., 2010; Gurumurthy et al., 2010; Nakada et al., 2010) . This would suggest that Lkb1 in this context is suppressing autophagy, whereas previously it has been reported to activate it following elevation of reactive oxygen species (Alexander et al., 2010) . Yet another phenotype potentially decreasing HSC viability was the noted increase in supernumerary centrosomes, aberrant mitotic spindles, and aneuploidy (Nakada et al., 2010) , which could be due to compromised BRSK2 activity (Alvarado-Kristensson et al., 2009) .
Recently, two groups generated mice where Lkb1 expression is specifically abolished in the T cell progenitors using the proximal p56lck-Cre promoter. The studies demonstrate severe deficiency in survival and proliferation of T cell progenitors and mature T cells in the absence of Lkb1 (Cao et al., 2010; Tamas et al., 2010) (Figure 1) . Also the survival of isolated peripheral T cells in vitro was dependent on Lkb1 (Tamas et al., 2010) . Transfection of thymocytes with constitutively active AMPKa2 partially rescued the thymocytes from cell death, indicating that thymocyte survival is mediated at least via AMPK pathway (Cao et al., 2010) . Thus, the common hematopoietic cell precursors and T cell precursors seem to have different requirement for AMPK signaling, although cell survival is defective in both cell types in the absence of Lkb1. The studies in hematopoietic cells have revealed an interesting aspect of Lkb1 biology: although being a tumor suppressor in some tissues, in others Lkb1 is required for survival.
Role of Lkb1 in nervous system
Lkb1 KO embryos exhibit severe deficiencies in development of neuronal tissues (Ylikorkala et al., 2001) . Since LKB1 orthologs in nematodes and fruit flies have been identified through their indispensable role in establishing polarity (Kemphues et al., 1988; Martin and St Johnston, 2003) and LKB1 regulates polarity also in some mammalian cells (Baas et al., 2004; Partanen et al., 2007) , it was of interest to generate models which would reveal the in vivo relevance of Lkb1 in establishing the axon-dendrite polarity in neuronal cells. Barnes et al. (2007) deleted Lkb1 in cerebral cortex of developing mice using Emx-Cre driver and showed that Lkb1 and its substrates BRSK1 and BRSK2 are required for axon specification in the studied neurons. This finding confirmed the previously described role of BRSK kinases in neuronal polarization (Kishi et al., 2005) , and placed Lkb1 as the upstream kinase required for the polarization to take place. Lkb1-activated BRSKs were shown to modify the cytoskeleton by phosphorylating MAPs (Barnes et al., 2007) . Studies in rat hippocampal neurons in vitro and developing rat cortical neurons in vivo agreed with the finding that Lkb1 is essential in establishing neuronal polarity; there, lack of either Lkb1 or STRAD prevented axon differentiation (Shelly et al., 2007) . Interestingly, overexpression of Lkb1 and STRAD resulted in formation of multiple axons. PKA-mediated phosphorylation of Lkb1 Ser 431 was shown to be required for the axon specification (Barnes et al., 2007; Shelly et al., 2007) . Thus, Lkb1 activity is modulated by upstream factors in a tissue-and context-specific manner.
Not only axon specification but also maintenance seems to be regulated via Lkb1 in some systems. Sun et al. (2011) reported, using the pancreatic and hypothalamic Rip2-Cre, that the mice developed hind-limb paralysis due to axon degeneration in thoracic spinal cord neurons at about 7-8 weeks of age (Figure 1) . The Rip2-Cre was found to be active also in spinal cord, especially in the thoracic segments. Deleting both AMPKa subunits did not result in axon degeneration or paralysis, and the authors speculated that in the absence of Lkb1, the neuronal polarization and axon degeneration defects might be mediated by BRSK kinase pathways (Sun et al., 2011) .
PJS and its mouse models
LKB1 was linked to human disease when its mutations were found to be causative for PJS (Hemminki et al., 1998; Jenne et al., 1998) . A major manifestation in PJS is the appearance of large occluding hamartomatous polyps in the GI tract (Giardiello and Trimbath, 2006) . Mice carrying one inactivated allele of Lkb1 (Lkb1 +/2 ) recapitulate PJS by developing hamartomatous GI polyps which are indistinguishable from PJS patient polyps (Bardeesy et al., 2002; Jishage et al., 2002; Miyoshi et al., 2002; Rossi et al., 2002) (Figure 2) , although in mice polyps appear more in the stomach and less in the small intestine. Polyps appear at 4-6 months (Udd et al., 2010) , and lead to lethality at an average age of 11 months due primarily to obstructions. Biallelic loss of wt Lkb1 is not a prerequisite for polyp formation, indicating that Lkb1 is a haploinsufficient tumor suppressor at least in the context of PJS polyps (Jishage et al., 2002; Miyoshi et al., 2002; Rossi et al., 2002) . Strong up-regulation of COX2 has been identified in the mouse and also PJS patient polyps (Rossi et al., 2002) , and COX2 inhibitors have been shown to be efficient suppressors of PJS polyps (Udd et al., 2004) . PJS is associated with elevated risk of cancer, especially in the GI tract, and also in breast, pancreas and gynecological cancers (Giardiello and Trimbath, 2006; Hearle et al., 2006; Mehenni et al., 2006) . Lkb1 +/2 mice in turn have been reported to have increased frequency of cancer in liver , bones (Robinson et al., 2008) , and endometrium (Contreras et al., 2008) (Figure 2) . Polyposis in Lkb1 +/2 mice is accelerated in a p53-deficient background (Wei et al., 2005; Takeda et al., 2006 ; our unpublished data) (Figure 2) , and p53 mutations are detected in the GI cancers of PJS patients (Miyaki et al., 2000) . Despite these observations, progression of the benign hamartomatous polyps to dysplasia or carcinoma is not clearly established possibly due to the rapid growth of the hamartomatous polyps leading to GI occlusions. As haploinsufficiency of Lkb1 is sufficient for polyp initiation (Jishage et al., 2002; Miyoshi et al., 2002; Rossi et al., 2002) though biallelic loss has been noted (Bardeesy et al., 2002) , loss of the remaining allele of Lkb1 may represent a progression step, although it has also been suggested that the loss of Lkb1 is associated with the resistance to progression in this context (Bardeesy et al., 2002) .
Mesenchymal Lkb1 loss leads to PJS-type polyposis in mice PJS polyps are classified as hamartomatous polyps thought to contain all the cell types of the surrounding tissue. However, it was recently noted that epithelial differentiation is disrupted in gastric and small intestinal polyps in Lkb1 mice, suggesting either that tamoxifen-induced Lkb1 loss at 6 weeks of age delayed the polyposis, or that mesenchymal loss of Lkb1 signaling is sufficient to drive hyperproliferation of epithelial tissue, but that coexisting epithelial mutations accelerate the process. This interesting aspect of Lkb1 signaling in tissue interactions is discussed later.
Other Lkb1 tumor mouse models Inactivating LKB1 mutations are associated with the development of cancer in several tissues. Various strategies of targeted inactivation of Lkb1 in mice, sometimes in combination of other tumorigenic mutations, have led to the development of various types and grades of tumors in multiple tissues, sometimes modeling human cancers in very useful ways as discussed below and summarized in Figure 2 .
Lung tumors
Lung cancer is the world's most lethal cancer, killing about 1.4 million people per year (http://www.who.int). Somatic LKB1 mutations occur in lung adenocarcinomas and cell lines, but the frequency seems to vary depending on ethnic background and smoking status up to 34% (Sanchez-Cespedes et al., 2002; Ji et al., 2007; Matsumoto et al., 2007; Koivunen et al., 2008; Strazisar et al., 2009; Gao et al., 2010) . Most LKB1 mutations are found from Caucasian, smoking men (Matsumoto et al., 2007; Koivunen et al., 2008) . Some reports identify lung cancer to be part of PJS cancer spectrum (van Lier et al., 2010) while others do not (Hearle et al., 2006; Mehenni et al., 2006) .
In mice, both homo-and heterozygous loss of Lkb1 combined with Kras activation by using inhaled Adeno-Cre, conditional Lkb1 mouse and lox-stop-lox Kras G12D allele resulted in high frequency of metastatic lung cancer, including squamous cell carcinoma (SCC), not previously reported in lung cancer mouse models (Figure 2) . Thus, it seems that in mice, both total loss and haploinsufficiency of Lkb1 promote lung carcinogenesis. The effect of Lkb1 deficiency was more dramatic than p21 or p53 loss in combination with Kras activation. Based on microarray profiling, Ji et al. (2007) speculated that Lkb1 inactivation influences the differentiation of lung cancer progenitor cells. This was the first report of a mouse model displaying metastatic lung cancer and a convincing evidence of the co-operation of Kras and Lkb1 mutations in promoting lung cancer initiation and metastasis.
Tumors of female reproductive tract
Women with PJS have high frequency of tumors in the reproductive tract. The cumulative cancer risks in ovary, uterus, or cervix of females with PJS vary at 13%-18% (van Lier et al., 2010) . Sporadic cervical cancer nearly always coincides with human papilloma virus (HPV) infection. Although HPV infection itself results in high-grade intraepithelial dysplasia, the lesion does not proceed to invasive cancer without other contributing factors. Wingo et al. (2009) first reported that 17 out of 86 cervical cancers were shown to carry inactivating mutations in LKB1. Many but not all of mutations were biallelic and occurred in all histological subtypes of cervical cancer. Strikingly, the median age of survival was only 13 months in patients with LKB1 loss, whereas patients with wt LKB1 survived for over 100 months. In addition, the authors identified biallelic LKB1 mutations in 5/7 studied cervical cancer cell lines, including the HeLa cell line, and demonstrated that LKB1 was lost already in vivo in the original tumor from which the cell line was originated, possibly explaining the aggressiveness of the tumor both in vivo and later in vitro in cell culture. This finding places LKB1 loss as an important candidate event to allow HPV-infected cells to proceed into cancer. While as yet targeted Lkb1 mouse models for cervical cancer have not been reported, Contreras et al. (2008) found that Lkb1 +/2 mice exhibited frequent uterine endometrial adenocarcinomas, developing in about half of the mice which survive until 55 weeks despite of polyposis (Figure 2) . The tumors were highly invasive, invading the myometrium towards the serosa. However, the tumor glands remained highly differentiated and were practically inseparable from normal endometrial glands. Also the polarity of tumor cells was intact. Endometrial adenocarcinoma was also induced when deleting Lkb1 in the uterine epithelial cells by introducing Adeno-Cre virus to uterine lumen in mice, which carried homozygous conditional Lkb1 alleles. While AMPK activity was decreased, no evidence for over-activated mTOR pathway was found (Contreras et al., 2008) . In studies on human endometrial tumors, the level of LKB1 expression was reduced predominantly in the most invasive tumors (.50% of most invasive, versus ,10% of least invasive) (Contreras et al., 2008) . Contreras et al. (2010) further generated an Sprr2f-Cre mouse line, which enables conditional inactivation of the desired gene only in the epithelial cells of uterine lumen and endometrial glands. Mice lacking Lkb1 from uterine epithelium died rapidly of invasive endometrial adenocarcinomas (Figure 2) . Similarly to Lkb1 +/2 mice, the tumors were well differentiated and retained the glandular structure. Notably, the Sprr2f-Cre model was completely penetrant and all female mice were dead approximately at 200 days. The uteri of the mice were shown to increase in mass with age, displaying malignant transformation throughout the tissue, whereas tumors in the Lkb1 +/2 mice were focal. Heterozygous deletion of Lkb1 using the Sprr2f-Cre line did not result in tumor development, arguing that in the context of endometrial tumors, Lkb1 heterozygosity is not enough to drive the transformation. In contrast to the endometrial adenocarcinomas noted in the Lkb1 flox/flox mice where recombination was induced by intrauterine Adeno-Cre injections (Contreras et al., 2008) , tumors in Sprr2f-Cre mice demonstrated activation of the mTOR pathway, and mTOR inhibition by rapamycin reduced the tumor burden significantly (Contreras et al., 2010) . This difference in mTOR activation between the two studies was not discussed by the authors, but as the mTOR pathway activation appears to be independent of LKB1 status in endometrial adenocarcinoma cell lines (Lu et al., 2008) , it is possible that mTOR activation and responsiveness to rapamycin in Sprr2f-Cre mice are independent of the Lkb1 KO. However, these mouse models developing endometrial cancer show that the frequent uterine cancer in PJS patients is recapitulated in mice, and that rapamycin or other mTOR targeting therapies may be effective in treatment of LKB1-deficient endometrial cancer.
Pancreatic tumors
Most studies indicate PJS patients are in increased risk of developing pancreatic cancer (Su et al., 1999 (Su et al., , 2001 Yee et al., 2003; Hearle et al., 2006; Mehenni et al., 2006) and some sporadic pancreatic cancers have been reported to harbor LKB1 mutations (Sahin et al., 2003) . Mouse models have revealed an important role of Lkb1 in regulating the function of both exo-and endocrine pancreas (discussed above) and provided evidence for the tumor suppressive role of Lkb1 in pancreas. In two studies, conditional Lkb1 mice were crossed to Pdx1-Cre driver, which targeted Lkb1 in the progenitors giving rise to the epithelial cells of the pancreatic islets, ducts, and acini Morton et al., 2010) (Figure 2) . All mice developed pancreatic cystic tumors, which were histologically classified as benign serous cystadenomas, and died by the age of 30 weeks. The model displayed also developmental defects: the histology of exocrine pancreas looked normal at birth but displayed less dense acini . The endocrine islets were smaller and fewer in number than those in wt. By postnatal day 8, acinar cells had disappeared and abnormal ductal structures were found. The authors concluded that the acinar-to-ductal cell metaplasia resulted from transdifferentiation. Increased Notch and Stat3 signaling were found in the pancreatic tissue. Studies in acinar cell polarity at E18.5 embryos revealed that despite of apparently normal acinar structure, the polarity of acinar cells was defective. AMPK, MARK, and SAD signaling were found reduced in the Lkb1-deficient pancreas (Figure 2) .
Using heterozygous Lkb1 allele in pancreas together with constitutively active Kras (Kras G12D/+ ), the mice developed malignant pancreatic ductal adenocarcinoma (PDAC) (Morton et al., 2010) (Figure 2 ). Premalignant lesions found from the mice were characterized by low p21 and p53 protein level and absent b-galactosidase staining, indicating absence of tissue senescence. Remarkably, the group studied 114 human PDACs and reported that 19% of them showed lowered LKB1 expression, which correlated with poor survival. Also low p21 expression was observed in these tumors, and p21 status correlated with poor survival. Accumulation of p53 was seen in tumors where LKB1 expression was normal, indicating that LKB1 and p53 mutations/inactivations may be alternative events in pancreatic cancer and both provide means to downregulate p21, in order to overcome KRAS-induced growth arrest and senescence (Morton et al., 2010) . Thus, pancreatic tumors seem to develop in the absence of LKB1, but their malignization requires additional genetic events such as KRAS activation.
Breast cancer
Human breast cancer has been reported to harbor frequent loss of heterozygosity (LOH) in chromosome area 19p13, where also LKB1 is situated (Forster et al., 2000; Shen et al., 2000; Yang et al., 2004) . LKB1 promoter methylation has been reported in half of sporadic papillary breast cancer specimens, although methylation was rare in other types of cancer (Esteller et al., 2000) . Regarding the breast cancer risk of PJS patients, a recent meta-analysis reported the cumulative risk of breast cancer to be 32%-54% (van Lier et al., 2010) . In mice, lack of Lkb1 in mammary glands leads to tumorigenesis. McCarthy et al. (2009) generated a mouse where Lkb1 deficiency is limited to the mammary gland using conditional Lkb1 under control of BLG-Cre (Figure 2) . Eight of 42 mice (19%) developed mammary gland tumors at 46-85 weeks latency. Histologically, the tumors mimicked the ductal carcinomas or solid papillary carcinomas, which are typical breast cancers for PJS patients (McCarthy et al., 2009 ). Nakau et al. (2002) reported that Lkb1 +/2 mice which survive long enough despite of GI polyps start developing preneoplastic foci in the liver from 30 weeks of age (Figure 2 ). Seventy percent of male, but only 20% of female Lkb1 +/2 mice aged over 50 weeks also developed hepatocellular carcinoma (HCC), which recapitulated human HCC types and were shown to have lost the wt copy of Lkb1. When crossing Lkb1 +/2 mice to p53 mutant mice, the formation of hepatic tumors was accelerated (Takeda et al., 2006) . Similarly, upon forced activation of Wnt signaling by constitutively active b-catenin at 1 year of age, development of HCC was accelerated (Miyoshi et al., 2009) (Figure 2) . The formation of preneoplastic lesions was, however, not increased. As already the preneoplastic foci were shown to have lost the wt allele of Lkb1, Miyoshi et al. (2009) suggested that initiation of the liver lesions results from loss of Lkb1, and other factors, such as activation of Wnt signaling, lead to progression into malignancy. The fact that complete deletion of Lkb1 in hepatocytes resulted in alterations of metabolism without tumorigenesis (Shaw et al., 2005; Woods et al., 2011) (Figure 1 ) may reflect the time-span required for the lesions to occur. Bone tumors Robinson et al. (2008) reported hind-limb paralysis in 2% (6/ 300) of about 1-year-old Lkb1 +/2 mice and found multiple benign osteogenic tumors in their spinal column (Figure 2) . Also 12 asymptomatic mice selected for further study were found to have osteogenic tumors in spinal column, and osteoblastosis in long bones (femur and tibia), indicating that the bone phenotype was multifocal. They speculated that the Lkb1-PTEN pathway might be important in development of this condition.
Liver tumors

Skin tumors
When Lkb1 +/2 mice or mice lacking Lkb1 specifically in keratin 14-expressing epidermal cells were exposed to a chemical carcinogen which is able to initiate tumorigenesis in various organs, 7,12-dimethylbenz(a)anthracene (DMBA), they developed SCCs in the skin with high frequency ( Figure 2 ). Also few SCCs in the lung were seen in these mice. All SCCs from Lkb1 heterozygous mice showed lack of wt allele in the tumor tissue, indicating that LOH is required for tumorigenesis in the formation of SCCs. AMPK signaling was reduced in the SCCs. However, when cell lines derived from the SCCs were reconstituted with Lkb1, they showed growth arrest, which was not reverted by inhibition of AMPK, indicating that other signaling pathways mediate the tumor suppression in this model. Inactivation of Rb pathway resulted in partial rescue of the growth arrest in these cells . This model provides support to the hypothesis that LKB1 loss promotes tumorigenesis especially in connection to chemical carcinogens as is also seen in lung cancer, where LKB1 mutations seem to correlate with tobacco exposure (Matsumoto et al., 2007; Koivunen et al., 2008) .
Prostate tumors
There are no reports of somatic LKB1 mutations in prostate cancer or increased prostate cancer risk in PJS patients. However, in mouse prostate, conditional deletion of Lkb1 by Ah-Cre was shown to lead to prostate intraepithelial neoplasia (PIN) (Pearson et al., 2008) (Figure 2) . AMPK activation and subsequent down-regulation in mTOR signaling were unaffected, suggesting that alternative kinases phosphorylate AMPK in the absence of Lkb1 in prostate. Increased Wnt signaling and decreased PTEN activity were reported, leading to activation of Akt pathway (Pearson et al., 2008) . Lkb1 loss has previously been reported to increase Wnt and reduce PTEN signaling (Spicer et al., 2003; Mehenni et al., 2005) , both shown to promote prostate neoplasia in mice (Wang et al., 2003; Bruxvoort et al., 2007) . Thus, activation of Wnt and Akt pathways, independent of mTOR, could be responsible for the development of PIN in this model. On the other hand, in prostate cancer cells, AMPK loss has been reported to promote proliferation (Zhou et al., 2009 ).
Tumors resulting from combined targeting of Lkb1 and Pten
The hypomorphic Lkb1 mouse (discussed under muscle phenotypes) expresses only 10%-20% of the amount of Lkb1 in wt in studied tissues (heart, skeletal muscle, liver), but the tumorigenicity of the mice was not discussed in the original paper (Sakamoto et al., 2005) . Contribution of the hypomorphic allele to tumor formation in mice was addressed by Huang et al. (2008) , who also crossed the hypomorphic Lkb1 mice to tumorprone Pten +/2 mice ( Figure 2) . Surprisingly, by 14 months, the ;Lkb1 +/+ or Pten +/2 ;Lkb1 flox/+ mice were treated with AMPK activators (metformin, phenformin, or A-769662), tumorigenesis was delayed and no tumors were found in animals treated with phenformin or A-769662 within 6 months, while 60% of control animals exhibited tumor growth. This study suggested that AMPK activation is very efficient tumor-preventing strategy at least in this experimental setting, and raises an interesting question whether rapamycin would result in similar or additive effects. Another recent study utilized conditional alleles of Lkb1 and Pten together with Ah-CreER and induced Cre recombination induced by b-napthtoflavone and tamoxifen injections at 6 weeks of age (Shorning et al., 2011) . This approach leads to Cre-mediated recombination in epithelia of several organs, including prostate, small intestine, stomach, liver, and bladder. Indeed, Ah-Cre line has been used to delete Lkb1 in prostate and small intestine epithelium (Pearson et al., 2008; Shorning et al., 2009) . Here, mice deficient of either Lkb1 or Pten did not develop tumors, but the compound mutants displayed reduced lifespan mainly due to bladder tumorigenesis and obstructed urine flow (Shorning et al., 2011) (Figure 2) , and significant increase in mTOR signaling was observed in the bladder of the double mutants, together with typical features of epithelialmesenchymal transition. Despite of Cre-mediated recombination which occurs also in the epithelium of small intestine, no intestinal tumors were detected, suggesting that activation of mTOR signaling via deleting both Pten, inhibitor of Akt signaling and Lkb1, activator of AMPK signaling, is leading to tumorigenesis only in some tissues, such as here in the bladder epithelium.
Lkb1 mediates messages between stromal and epithelial tissues via Tgfb signaling?
Inactivating Lkb1 in the smooth muscle lineage is sufficient for GI polyposis (Katajisto et al., 2008) as discussed above. In this model attenuated Tgfb signaling from stromal cells to epithelial cells was associated with increased epithelial proliferation. Also, other models point out a role for Lkb1 mediating Tgfb signaling between epithelial and mesenchymal signaling. The endothelium-specific deletion of Lkb1 resulted in loss of Tgfb secretion, followed by loss of supporting smooth muscle cells resulting in dilated and distorted vasculature (Londesborough et al., 2008) . Cell line studies in mouse embryonic fibroblasts (MEFs) showed that Lkb1-deficient MEFs display reduced Tgfb signaling followed by defective differentiation into myofibroblasts and abnormalities in the actin cytoskeleton . Thus, the in vitro study revealed that deficiency of Lkb1 leads to attenuated Tgfb signaling resulting in defects in smooth muscle cell lineage differentiation and suggested that stromal Lkb1 acts as a 'landscaper' tumor suppressor gene .
Similar mechanisms have been proposed to be at play in a model where the Tgfb type II receptor (TgfbRII) gene deletion from stromal fibroblasts leads to invasive carcinoma of the forestomach (Bhowmick et al., 2004) . As these TgfbRII mutant mice develop also intraepithelial neoplasia in prostate, it would be interesting to study the status of Tgfb signaling in the Lkb1-inactivation-based prostate tumor model (Pearson et al., 2008) . A landscape mechanism has also been suggested in mice where SMAD4 is deleted in T cells leading to epithelial tumors throughout the GI tract (Kim et al., 2006) , and upon stromal inactivation of Bmp receptor II (BMPRII) gene which leads to hamartomatous polyps in the colorectum (Beppu et al., 2008) . Both SMAD4 and BMPRII are mutated in a hamartomatous Juvenile polyposis syndrome closely resembling PJS. Taken together, these studies establish stromal TGFb family signaling as an important growth restrictive signal to GI epithelial cells and implicate these pathways in human polyposis syndromes.
It is well established that stromal cells associated with tumors are frequently abnormally activated, but the studies investigating the role of stromal cells in initiating tumor growth are as yet scarce. There is evidence, however, that inactivating known tumor suppressor genes other than Lkb1, and deregulation of growth regulating pathways other than Tgfb, in stromal cells lead to epithelial tumors. For example, targeted deletion of PI3K-Akt pathway inhibitor gene PTEN in mouse mammary gland fibroblasts results in mammary epithelial tumors, and breast cancer patients frequently harbor loss of PTEN expression in the tumor stroma (Trimboli et al., 2009) . In general, the role of signaling defects in local tissue microenvironment leading to epithelial tumorigenesis is increasingly recognized as an important contributor to tumor formation and spread (Pietras and Ostman, 2010) . Therefore, studying the effects of Lkb1 deletion in different stromal cell compartments will likely greatly contribute to our knowledge on its mode of tumor suppressor.
Conclusions
Mice with targeted Lkb1 mutations have demonstrated the in vivo role of Lkb1 in regulation of metabolism, polarity, and the cytoskeleton which defined its roles also as a tumor suppressor in various tissue types. Of the downstream substrates, AMPK appears to be important in mediating many of the effects, yet there are clear examples where other downstream pathways contribute. Solid genetic evidence of particular pathways being critical for various Lkb1 functions awaits the generation of new mouse models. This holds true also for identification of the critical signals altered in stromal-epithelial signaling in PJS. Modeling the substrates and pathways mediating the tumor suppressive function of Lkb1 is of extremely high relevance as it could allow development of targeted therapies against Lkb1-deficient cancers, such as the world's most lethal cancer, lung cancer.
